Is it effective to use osimertinib in Kemena-resistant brains without mutations?

In the case of Kemena resistance and no mutational brain metastasis, the effect of using osimertinib is a complex issue that needs to be considered from multiple aspects.

Osimertinib is a third-generation EGFR targeted drug, mainly targeting lung cancer patients with EGFR mutations, including T790M mutations. It achieves the purpose of treating lung cancer by inhibiting the growth and spread of tumor cells. For patients who are resistant to Kemena, if the resistance mechanism is related to EGFR mutations, especially the T790M mutation, then osimertinib may have a significant therapeutic effect.

Lung cancer brain metastasis is a type of metastatic lung cancer that is difficult to treat. Due to the existence of the blood-brain barrier, many drugs have difficulty entering the brain to achieve effective therapeutic concentrations. However, osimertinib has the ability to break through the blood-brain barrier and therefore has certain advantages in the treatment of brain metastases from lung cancer. Clinical data shows that osimertinib can prolong the progression-free survival of patients with lung cancer and brain metastases, indicating that it has a good control effect on brain metastases.

For patients with brain metastasis who are resistant to Kemena and do not have EGFR mutations (including T790M mutations), the effect of using osimertinib may be relatively limited. Because the efficacy of osimertinib mainly depends on the inhibitory effect on EGFR mutations, and in the absence of mutations, the lack of its target may lead to poor efficacy of the drug. At this time, other treatments or drug combination strategies need to be considered.

It’s important to note that every patient’s situation is different. Therefore, before using osimertinib, it is recommended to conduct detailed genetic testing to clarify the mechanism of resistance and whether there are treatable targets. At the same time, doctors should develop personalized treatment plans based on factors such as the patient's overall condition, severity of illness, and personal wishes.